Pituitrin
PreclinicalSmall molecule
Pituitrin is one of 47 small molecule programs targeting Pulmonary Hypertension. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
46
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
53 competitors in Pulmonary Hypertension
#DrugCompanyPhaseTrials
1Viagra
VViatris Specialty LLC
Approved
Letairis
GileadApproved
Adempas
BayerApproved
Cialis
Eli LillyApproved
Tracleer
Johnson & JohnsonApproved
Remodulin
United TherapeuticsApproved
Opsumit
Johnson & JohnsonApproved
Primacor
SanofiApproved
Levitra
BayerApproved
Uptravi
Johnson & JohnsonApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Pulmonary Hypertension1 trial
After Cardiac Surgery1 trial
Small Doses of Pituitrin Versus Norepinephrine for the Management of Vasoplegic Syndrome in Patients After Cardiac Surgery
Unknown status·—·N/A·NCT03106831·120 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pituitrin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- QQianfoshan Hospital